The estimated Net Worth of Venture Capital Iii, L.P.Ve... is at least $16.5 millió dollars as of 15 June 2015. Venture Ve owns over 320,000 units of Ocular Therapeutix Inc stock worth over $109,779 and over the last 10 years Venture sold OCUL stock worth over $16,434,000.
Venture has made over 2 trades of the Ocular Therapeutix Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Venture sold 320,000 units of OCUL stock worth $7,040,000 on 15 June 2015.
The largest trade Venture's ever made was selling 427,000 units of Ocular Therapeutix Inc stock on 10 June 2015 worth over $9,394,000. On average, Venture trades about 249,000 units every 2 days since 2014. As of 15 June 2015 Venture still owns at least 13,007 units of Ocular Therapeutix Inc stock.
You can see the complete history of Venture Ve stock trades at the bottom of the page.
Over the last 10 years, insiders at Ocular Therapeutix Inc have traded over $73,512,800 worth of Ocular Therapeutix Inc stock and bought 6,361,550 units worth $38,632,070 . The most active insiders traders include Management Inc. Opaleye, Road Llc Summer és Venture Management Co. V, L.... On average, Ocular Therapeutix Inc executives and independent directors trade stock every 43 days with the average trade being worth of $999,228. The most recent stock trade was executed by Sanjay Nayak on 23 August 2024, trading 1,832 units of OCUL stock currently worth $16,525.
ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib
Ocular Therapeutix Inc executives and other stock owners filed with the SEC include: